Breast Cancer | Specialty

Some With Micropapillary Urothelial Carcinoma May Benefit From HER2-Targeted Treatment

February 27th 2014

Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent trastuzumab, which has vastly increased the odds of survival for eligible patients with breast cancer.

Integrating Genetic Counseling Into an Oncology Practice Can Benefit High-Risk Families

February 26th 2014

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

Dr. Tripathy on Markers of Resistance in Breast Cancer

February 26th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses markers of resistance in patients with HER2+ breast cancer.

Preventative Ovarian Surgery in BRCA1 Mutation Carriers More Beneficial Before Age 35

February 24th 2014

For the first time, physicians have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.

Dr. Jhaveri on T-DM1 in the Neoadjuvant Setting

February 21st 2014

Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.

Dr. Goncalves on the ESR1 Mutation in Breast Cancer

February 19th 2014

Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, describes research involving the ESR1 gene mutation in breast cancer.

Genetic Analysis of Remote Population May Advance Breast Cancer Prevention and Treatment

February 18th 2014

Using blood samples collected from the Andean villagers, the laboratory at the UC Davis Genome Center uses a variety of high-throughput genetic analysis techniques to screen for genetic differences.

PARP Inhibitor BMN 673 Advances in Breast Cancer Study

February 18th 2014

As PARP inhibitors continue to emerge as a novel class of anticancer agents, BMN 673 has entered late-stage clinical development as a treatment for patients with locally advanced or metastatic breast cancer whose tumors test positive for germline BRCA1/2 mutations.

Visualizing Cancer Cells With the Help of High-tech Eyewear

February 17th 2014

High-tech eyewear could soon help surgeons remove tumors from patients with breast cancer or melanoma by allowing them to see the margins of tumors more accurately when a dye is used to fluoresce a tumor's borders.

Dr. Finn on the Potential of CDK Inhibition

February 13th 2014

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the potential of CDK inhibition in breast cancer and other malignancies.

Dr. Shulman on Chemotherapy in Adjuvant Breast Cancer

February 12th 2014

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.

Dr. Hershman on Exercise and AI-Associated Arthralgias

February 7th 2014

Dawn L. Hershman, MD, MS, describes the HOPE study, which looked at the effect of exercise versus usual care on aromatase inhibitor-associated arthralgias (joint pain) in women with breast cancer.

Robert McCormack Explains the CellSearch CTC Test

February 5th 2014

Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.

Phase II Palbociclib Results Confirm Effectiveness in Breast Cancer

February 3rd 2014

Final results from the phase II PALOMA-1 trial continue to support the dramatic efficacy of palbociclib plus letrozole in postmenopausal patients with locally advanced or newly diagnosed estrogen receptor ER-positive, HER2-negative metastatic breast cancer.

Dr. Shapiro on Preventative Drugs in Breast Cancer

January 27th 2014

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the underutilization of preventative drugs for breast cancer.

Dr. von Minckwitz on the Rationale of PENELOPE

January 23rd 2014

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses the rationale behind the phase III PENELOPE trial.

Conclusion: Future Direction of Breast Cancer Treatment

January 22nd 2014

Preventing Skeletal-Related Events in Breast Cancer

January 22nd 2014

Chemotherapeutics in Metastatic Breast Cancer

January 22nd 2014

CDK4/6 Inhibitors in Metastatic Breast Cancer

January 22nd 2014